Method and device for optimally altering stimulation energy to maintain capture of cardiac tissue

• US 6,615,082 B1
• Filed: 10/05/2000
• Issued: 09/02/2003
• Est. Priority Date: 05/15/2000
• Status: Expired due to Fees

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Mandell, Lee J.
• Primary Examiner(s): Vo, Hieu T.
• Assistant Examiner(s): Hoang, Johnny H.
• Application Number:
  US09/685,331
• Time in Patent Office: 1,062 Days
• Field of Search: 607/9, 607/11, 607/17, 607/12, 607/28, 607/5
• US Class Current: 607/11
• CPC Class Codes: A61N 1/3712 Auto-capture, i.e. automatic adjustment of the stimulation threshold

Abstract

An improved system and method for performing automatic capture/threshold detection in an implantable cardiac stimulation device or any device capable of stimulating some organ or tissue in the body. Prior art systems determine the stimulation threshold of the cardiac tissue by detecting an evoked response to a fixed duration stimulation pulse and then increasing the amplitude of the stimulation pulse by a predetermined safety margin value. Such systems are inherently based upon a belief that the chronaxie of the strength-duration curve for a particular patient is essentially fixed and that the rheobase is variable. While this may be true at some times during the patient'"'"'s life, e.g., during the acute phase after lead implantation absent drug effects, it is reported that drugs alone may alter the chronaxie and it is believed that other factors may also affect the chronaxie either alone or in combination with the rheobase.

Claims

1. An implantable stimulation device configured for stimulating muscle tissue through at least one electrode implanted in electrical contact with selected muscle tissue, the stimulation device comprising:

a pulse generator configured for electrical coupling to the electrode and configured to generate stimulation pulses at a controlled energy level to thereby stimulate the muscle tissue, wherein the controlled energy level is defined by a set of characteristics including an amplitude component and a duration component;

a detection circuit configured for electrical coupling to the electrode and configured to receive signals for determining the presence or absence of an evoked response to each of the stimulation pulses;

a controller, coupled to the pulse generator and the detection circuit, for increasing the controlled energy level from a first energy level to a second energy level in response to a loss-of-capture criteria related to the absence of an evoked response to at least one stimulation pulse generated at the first energy level; and

wherein

the first energy level has a first amplitude component and a first duration component and the second energy level has a second amplitude component and a second duration component, wherein the second amplitude component exceeds the first amplitude component and the second duration component exceeds the first duration component.

2. The implantable stimulation device of claim 1 wherein the set of characteristics for each energy level is determined by the controller.

3. The implantable stimulation device of claim 1 wherein the set of characteristics for each energy level is predetermined.

4. The implantable stimulation device of claim 1 wherein the set of characteristics for each energy level is remotely programmable.

5. The implantable stimulation device of claim 1 wherein the relationship between the amplitude and duration components is predominantly defined by an essentially linear relationship specified by the equation:

6. The implantable stimulation device of claim 5 wherein the slope is between 0.3 and 3.0 volts/millisecond.

7. The implantable stimulation device of claim 6 wherein the slope is essentially 1.0 volts/millisecond and the offset is a function of a strength-duration curve characterized by a chronaxie and a rheobase.

8. The implantable stimulation device of claim 7 wherein values corresponding to the chronaxie and rheobase are remotely programmable.

9. The implantable stimulation device of claim 7 wherein the controller periodically determines the chronaxie and rheobase.

10. The implantable stimulation device of claim 7 wherein the value of the offset is defined by the equation:

11. The implantable stimulation device of claim 7 wherein the offset is defined by the equation:

12. The implantable stimulation device of claim 1 additionally comprising a table for defining a plurality of energy levels defined by amplitude and duration components.

13. The implantable stimulation device of claim 12 wherein the energy levels defined within the table include at least one pair of sequential energy levels where the amplitude component is essentially the same between the sequential energy levels and the duration component increases between the sequential energy levels.

14. The implantable stimulation device of claim 12 wherein the energy levels defined within the table include at least one pair of sequential energy levels where the amplitude component increases between sequential energy levels and the duration component decreases between sequential energy levels.

15. The implantable stimulation device of claim 9 wherein a starting controlled energy level having an amplitude component and a duration component is determined in response to the strength-duration curve and an initial controlled energy level for delivery by the pulse generator is determined by increasing both amplitude and duration components of the starting controlled energy level to achieve a safety margin from the determined strength-duration curve.

16. The implantable stimulation device of claim 15 wherein the initial controlled energy level is greater than the starting controlled energy level by a variable safety margin.

17. A method for stimulating a patient'"'"'s body tissue, the method comprising the steps of:

periodically delivering a stimulation pulse to the patient'"'"'s body tissue, the stimulation pulse having a controlled energy level, wherein the controlled energy level is defined by a set of characteristics including an amplitude component and a duration component;

detecting the presence or absence of an evoked response generated by the patient'"'"'s body tissue in response to the stimulation pulse during a detection window;

determining whether a loss-of-capture criteria is satisfied in response to the absence of an evoked response to at least one stimulation pulse delivered at a first energy level; and

concurrently increasing both the amplitude and duration components of the controlled energy level in response to the loss-of-capture criteria until a capture criteria is met.

18. The method of claim 17 additionally comprising the step of periodically determining the set of characteristics for each energy level.

19. The method of claim 17 additionally comprising the step of predetermining the set of characteristics for each energy level.

20. The method of claim 17 additionally comprising the step of remotely programming the set of characteristics for each energy level.

21. The method of claim 17 wherein the step of increasing the amplitude and duration components of the controlled energy level is performed according to an essentially linear relationship specified by the equation:

22. The method of claim 21 additionally comprising the step of setting the slope to a value between 0.3 and 3.0 volts/millisecond.

23. The method of claim 22 additionally comprising the steps of:

setting the slope to a value of essentially 1.0 volts/millisecond; and

setting the offset to a value that is a function of a determined strength-duration curve characterized by a chronaxie and a rheobase.

24. The method of claim 23 additionally comprising the step of setting the offset to a value defined by the equation:

25. The method of claim 23 additionally comprising the step of setting the offset to a value defined by the equation:

26. The method of claim 23 additionally comprising the step of periodically determining the chronaxie and rheobase.

27. The method of claim 17 additionally comprising the step of storing within a table a plurality of energy levels defined by amplitude and duration components.

28. The method of claim 27 additionally comprising the step of storing within the table at least one pair of sequential energy levels where the amplitude component is essentially the same between the sequential energy levels and the duration component increases between the sequential energy levels.

29. The method of claim 27 additionally comprising the step of storing within the table include at least one pair of sequential energy levels where the amplitude component increases between sequential energy levels and the duration component decreases between sequential energy levels.

30. The method of claim 23 additionally comprising the steps of:

determining a starting controlled energy level having an amplitude component and a duration component in response to the determined strength-duration curve; and

determining an initial controlled energy level for delivery by the pulse generator by increasing both the amplitude and duration components of the starting controlled energy level to achieve a safety margin from the determined strength-duration curve.

31. The method of claim 30 additionally comprising the step of setting the initial controlled energy level to a value greater than the starting controlled energy level by a variable safety margin.

32. An implantable stimulation device configured for stimulating muscle tissue through at least one electrode implanted in electrical contact with selected muscle tissue, the stimulation device comprising:

a pulse generator configured for electrical coupling to the electrode and configured to generate stimulation pulses at a controlled energy level to thereby stimulate the muscle tissue, wherein the controlled energy level is defined by a set of characteristics including an amplitude component and a duration component;

a detection circuit configured for electrical coupling to the electrode and configured to receive signals for determining the presence or absence of an evoked response to each of the stimulation pulses;

a controller, coupled to the pulse generator and the detection circuit, for increasing the controlled energy level from a first energy level to a second energy level in response to a loss-of-capture criteria related to the absence of an evoked response to at least one stimulation pulse generated at the first energy level; and

wherein

the controlled energy level is increased according to a relationship between the amplitude and duration components that is predominantly defined by an essentially linear relationship specified by the equation;

33. The implantable stimulation device of claim 32 wherein the set of characteristics for each energy level is determined by the controller.

34. The implantable stimulation device of claim 32 wherein the set of characteristics for each energy level is predetermined.

35. The implantable stimulation device of claim 32 wherein the set of characteristics for each energy level is remotely programmable.

36. The implantable stimulation device of claim 32 wherein the slope is between 0.3 and 3.0 volts/millisecond.

37. The implantable stimulation device of claim 36 wherein the slope is essentially 1.0 volts/millisecond and the offset is a function of a strength-duration curve characterized by a chronaxie and a rheobase.

38. The implantable stimulation device of claim 37 wherein the offset is defined by the equation:

39. The implantable stimulation device of claim 37 wherein the offset is defined by the equation:

40. The implantable stimulation device of claim 37 wherein the controller periodically determines the chronaxie and rheobase.

41. The implantable stimulation device of claim 32 additionally comprising a table for defining a plurality of energy levels defined by amplitude and duration components.

42. The implantable stimulation device of claim 41 wherein the energy levels defined within the table include at least one pair of sequential energy levels where the amplitude component is essentially the same between the sequential energy levels and the duration component increases between the sequential energy levels.

43. The implantable stimulation device of claim 41 wherein the sets of energy levels defined within the table include at least one pair of sequential energy levels where the amplitude component increases between sequential energy levels and the duration component decreases between sequential energy levels.

44. The implantable stimulation device of claim 40 wherein a starting controlled energy level having an amplitude component and a duration component is determined in response to the strength-duration curve and an initial controlled energy level for delivery by the pulse generator is determined by increasing both amplitude and duration components of the starting controlled energy level to achieve a safety margin from the determined strength-duration curve.

45. The implantable stimulation device of claim 44 wherein the initial controlled energy level is greater than the starting controlled energy level by a variable safety margin.

46. The implantable stimulation device of claim 44 wherein the starting controlled energy level has an amplitude component of twice the rheobase and a duration component of the chronaxie.

47. The implantable stimulation device of claim 44 wherein the starting controlled energy level corresponds to the intersection between the strength-duration curve and the essentially linear relationship defining the controlled energy level.

48. An implantable stimulation device for stimulating a patient'"'"'s body tissue, the stimulation device comprising:

means for periodically delivering a stimulation pulse to the patient'"'"'s body tissue, the stimulation pulse having a controlled energy level, wherein the controlled energy level is defined by a set of characteristics including an amplitude component and a duration component;

means for detecting the presence or absence of an evoked response generated by the patient'"'"'s body tissue in response to the stimulation pulse; and

means for determining whether a loss-of-capture criteria is satisfied in response to the absence of an evoked response to at least one stimulation pulse;

means for increasing the controlled energy level when the loss-of-capture criteria is satisfied according to a relationship between the amplitude and duration components that is predominantly defined by an essentially linear relationship specified by the equation;

49. An implantable cardiac stimulation device comprising:

pulse generator means for providing stimulation pulses to cardiac tissue, such stimulation pulses having selectable pulse shapes, each pulse being defined by a pulse amplitude and pulse width;

detection means for detecting the presence or absence of an evoked response corresponding to each stimulation pulse and indicative thereof of the presence or absence of capture;

control means for controlling the stimulation pulse amplitude and pulse width in response to a loss of capture criteria; and

wherein

the control means simultaneously increases both the pulse amplitude and pulse width until a capture criteria is met.

50. The stimulation device of claim 49 wherein the pulse amplitude and pulse width are related by the equation:

51. The stimulation device of claim 50 wherein the slope is in the range of 0.3 to 3.0 volts/millisecond.

52. The stimulation device of claim 50 wherein the control means includes means for determining the chronaxie and rheobase of the cardiac tissue.

53. The stimulation device of claim 52 wherein the value of the offset is defined by the equation:

54. The stimulation device of claim 52 wherein the value of the offset is defined by the equation: